Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous NK Cells + IL-2 in Metastatic Melanoma or Kidney Cancer
NCT00328861Phase 2
Key facts
- Status
- Completed
- Start
- May 2006
- Primary completion
- Jul 2007
- Countries
- 1
- Sponsor
- National Cancer Institute
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Conditions
- melanomametastatic renal cell carcinoma (mRCC)
01
Overview
Phase 2, open-label trial of autologous natural killer cells in melanoma and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response at 5 years. Started May 2006; status: completed.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
NK Cells + IL-2: Melanoma
Autologous NK cells + IL-2 + Lymphodepletion in Metastatic Melanoma
NK Cells + IL-2: Renal Cell
Autologous NK cells + IL-2 + Lymphodepletion in Metastatic Kidney Cancer
03
Endpoints
Primary
Objective Response
Secondary
Safety
Beyond the preview
Go deeper on NCT00328861.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00328861.